Filter Results:
(1,253)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
Amy W. Schulman
Amy W. Schulman is an accomplished business leader, widely recognized for growing and stabilizing global businesses, commitment to people, strategic judgment, and efforts to advance women and promote inclusive workplace cultures.
Ms. Schulman joined Harvard... View Details
- 05 Sep 2023
- Book
Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential
acid deficiency. When the drug was reformulated with folic acid, it passed its efficacy trials, eventually becoming a multibillion-dollar pharmaceutical that helped thousands of lung cancer patients. How to fail intelligently Edmondson,... View Details
Keywords: by Michael Blanding
- Web
Hiring Organizations
Partners Recove Recur Software RedBird Capital Partners Redpoint Ventures REEF Reflex Technologies Reformation Regeneron Pharmaceuticals Relari Relay Investments RenWave Kore Replica Restaurant Brands International Rethink Education REV... View Details
- 15 May 2007
- First Look
First Look: May 15, 2007
Working PapersI'll Have the Ice Cream Soon and the Vegetables Later: Decreasing Impatience over Time in Online Grocery Orders Authors:Todd Rogers, Katherine L. Milkman, and Max H. Bazerman Abstract How do decisions for the near future differ from decisions for the... View Details
Keywords: Martha Lagace
Regina E. Herzlinger
Regina E. Herzlinger is the Nancy R. McPherson Professor of Business Administration at the Harvard Business School. She was the first woman to be tenured and chaired at Harvard Business School and serve on many established and start-up corporate health care/medical... View Details
- 25 Jul 2023
- Research & Ideas
Could a Business Model Help Big Pharma Save Lives and Profit?
cross-sector and cross-border partnerships needed to execute the model. Adding new information about how pharmaceutical companies handle global public health challenges. Jessica Martinez, a former Big Pharma executive who joined the Bill... View Details
- Article
Extending the Role of Headquarters Beyond the Firm Boundary: Entrepreneurial Alliance Innovation
By: Jaeho Kim and Andy Wu
Prior research on corporate headquarters (CHQ) characteristics identifies the impact of CHQ location and composition on the innovation outcomes of internal subsidiaries. However, given that external strategic alliances with high-tech entrepreneurial firms represent a... View Details
Keywords: Alliance; Innovation; Corporate Headquarters; Geographic Proximity; Entrepreneurship; Corporate Strategy; Alliances; Joint Ventures; Innovation and Invention; Business Headquarters; Geographic Location
Kim, Jaeho, and Andy Wu. "Extending the Role of Headquarters Beyond the Firm Boundary: Entrepreneurial Alliance Innovation." Art. 15. Special Issue on Corporate Headquarters. Journal of Organization Design 8 (2019): 1–35.
- April 2019 (Revised January 2025)
- Case
Wendell Weeks at Corning Inc.: Extending a History of Life-Changing Innovations (A)
By: Ryan Raffaelli, David G. Fubini and Aldo Sesia
This case examines the leadership challenges associated with maintaining a culture of innovation in established organizations. It asks students to step into the shoes of a leader faced with making several tough decisions about when to invest (or to stop investing) in... View Details
Keywords: Innovation and Invention; Organizational Culture; Innovation Leadership; History; Technological Innovation; Investment; Decision Making
Raffaelli, Ryan, David G. Fubini, and Aldo Sesia. "Wendell Weeks at Corning Inc.: Extending a History of Life-Changing Innovations (A)." Harvard Business School Case 419-003, April 2019. (Revised January 2025.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- 11 Sep 2012
- Working Paper Summaries
Spatial Organization of Firms: Internal and External Agglomeration Economies and Location Choices Through the Value Chain
Keywords: by Juan Alcácer & Mercedes Delgado
- June–July 2019
- Article
A Methodology for Operationalizing Enterprise IT Architecture and Evaluating Its Modifiability
By: Robert Lagerström, Alan MacCormack, David Dreyfus and Carliss Y. Baldwin
Recent contributions to information systems theory suggest that the primary role of a firm’s information technology (IT) architecture is to facilitate, and therefore ensure the continued alignment of a firm’s IT investments with a constantly changing business... View Details
Keywords: Enterprise Architecture; Modularity; Information Systems; Modifiability; Design Structure Matrix
Lagerström, Robert, Alan MacCormack, David Dreyfus, and Carliss Y. Baldwin. "A Methodology for Operationalizing Enterprise IT Architecture and Evaluating Its Modifiability." Complex Systems Informatics and Modeling Quarterly 19 (June–July 2019): 75–98.
Karim R. Lakhani
Karim R. Lakhani is the Dorothy & Michael Hintze Professor of Business Administration at the Harvard Business School. He specializes in technology management, innovation, digital transformation and artificial... View Details
Max H. Bazerman
Max H. Bazerman is Jesse Isidor Straus Professor of Business Administration at the Harvard Business School. His recent books... View Details
- 10 Oct 2007
- First Look
First Look: First Look: October 10
Hamermesh, Faculty Chair of the Harvard Business Healthcare Initiative, discuss the barriers to personalized medicine and suggest ways to overcome them. The blockbuster model for developing drugs, the authors point out, is still what most major View Details
Keywords: Martha Lagace
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
- 2010
- Working Paper
Accelerating Energy Innovation: Insights from Multiple Sectors
By: Rebecca Henderson and Richard G. Newell
A combination of concerns about climate change and energy security has recently led to significant increases in public funding for energy R&D. Some commentators are suggesting that these increases need to be sustained, and are advocating for increases of as much as... View Details
Keywords: Innovation and Management; Technological Innovation; Knowledge Use and Leverage; Research and Development; Pollutants; Climate Change; Energy Industry
Henderson, Rebecca, and Richard G. Newell. "Accelerating Energy Innovation: Insights from Multiple Sectors." Harvard Business School Working Paper, No. 10-067, February 2010. (Revised February 2011.)
- 20 Nov 2007
- First Look
First Look: November 20, 2007
discipline to nationalized banks. Pharmaceutical Regulation in the United States and Europe Author:Arthur Daemmrich Periodical:Focus on Law Studies 23, no 1 (fall 2007): 8-11 Read the full paper:... View Details
Keywords: Martha Lagace
- 09 May 2024
- Research & Ideas
Called Back to the Office? How You Benefit from Ideas You Didn't Know You Were Missing
knowledge sharing outside one’s core department. That is one implication of a new study about how knowledge is shared that focuses on academia, but may offer lessons for technology, pharmaceutical development, and other STEM industries.... View Details
Keywords: by Ben Rand
- January 2009
- Case
When Supply is of Public Interest: Roche & Tamiflu
The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic... View Details
Keywords: Global Strategy; Health Pandemics; Distribution; Logistics; Production; Supply Chain Management; Performance Capacity; Pharmaceutical Industry
Watson, Noel H., Laura Rock Kopczak, and Prashant Yadav. "When Supply is of Public Interest: Roche & Tamiflu." Harvard Business School Case 609-061, January 2009.